Por Derek Francis
(Reuters) – The Kovid-19 vaccine from AstraZeneca PLC and the University of Oxford works well as a third booster dose, raising antibodies against coronavirus spike proteins among study participants, the Financial Times reported on Wednesday.
The news has come at a time when vaccine manufacturers have warned that the world will need annual booster vaccines or new vaccines to deal with variants of the virus, but some scientists question whether such vaccines are needed.
The FT quoted a person familiar with the results of the study, which showed that the antibody response to the booster vaccine was “quite strong against any form” and dispelled the apprehension that one-time use of adenovirus Can not be done.
AstraZeneca and the University of Oxford did not immediately respond to a request for Reuters comment about the Oxford study, which is yet to be published.
The vaccine uses a new technology that employs a modified version of the adenovirus that causes the common flu as vectors to send instructions to human cells.
The concept has led some scientists to fear that if annual vaccination becomes necessary to combat new forms the dosage will lose potency.
It is not known when Oxford and AstraZeneca plan to publish the study data, the FT said.
